Home › NDC Lookup › RxCUI directory › RxCUI 825130

24 HR mesalamine 375 MG Extended Release Oral Capsule — RxCUI 825130

RxNorm drug concept · Semantic clinical drug
RxCUI 825130 Semantic clinical drug · SCD ● Current RxNorm concept 16 FDA products 20 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI825130
Official name24 HR mesalamine 375 MG Extended Release Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asmesalamine 0.375 GM 24HR Extended Release Oral Capsule; mesalazine 375 MG 24 HR Extended Release Oral Capsule
FDA products mapped16
Package NDCs mapped20
Reported Medicaid activity (SDUD)29,026 prescriptions · 43 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Mesalamine Rectal: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Mesalamine rectal works by calming the inflammation directly in the lining of your rectum and lower colon — the area affected by your condition. It blocks some of the chemical sign...
  • What exactly is this medication doing for my colitis?
  • Treatment is typically continued for 3 to 6 weeks depending on your symptoms and what your doctor sees during examination. It's important to keep using it for the full course your...
  • How long do I need to use it before it starts working?
📖 Read our full Mesalamine Rectal guide →

🕸️ Concept Web — How 24 HR mesalamine 375 MG Extended Release Oral Ca... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 24 HR mesalamine 375 MG Extended Release Oral Capsule RxCUI 825130

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Mesalamine 52582
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Apriso 825131
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Mesalamine Extended Release Oral Capsule 372783
    • Mesalamine Oral Product 1165714
    • Mesalamine Pill 1165715
    • Mesalamine Extended Release Oral Capsule [Apriso] 825133
    • Apriso Oral Product 1168587
    • Apriso Pill 1168588
    • Extended Release Oral Capsule 316943
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Mesalamine 375 MG SCDC · 825129
  • Mesalamine Extended Release Oral Capsule SCDF · 372783
  • Mesalamine Oral Product SCDG · 1165714
  • Mesalamine Pill SCDG · 1165715

Brand-Name Concepts

📦 FDA Products & Package NDCs

16 products · 20 package NDCs
20 package NDCs map to RxCUI 825130 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00093-9224-89 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0093-9224-89) mesalamine Teva Pharmaceuticals USA, Inc. 2021-01-05
00378-1375-78 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (0378-137... Mesalamine Mylan Pharmaceuticals Inc. 2019-11-26
00832-6056-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0832-6056-12) Mesalamine Upsher-Smith Laboratories, LLC 2023-07-25
31722-0489-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (31722-489-12) MESALAMINE Camber Pharmaceuticals, Inc. 2025-08-13
46708-0724-35 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (46708-724-35) MESALAMINE Alembic Pharmaceuticals Limited 2022-11-03
46708-0724-91 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (46708-724-91) MESALAMINE Alembic Pharmaceuticals Limited 2022-11-03
50268-0577-15 50 BLISTER PACK in 1 BOX (50268-577-15) / 1 CAPSULE, EXTEND... Mesalamine AvPAK 2023-01-16
50742-0371-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (50742-37... Mesalamine Ingenus Pharmaceuticals, LLC 2024-09-23
51407-0976-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (51407-976-12) Mesalamine Golden State Medical Supply, Inc. 2026-02-09
59651-0397-08 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (59651-397-08) Mesalamine Aurobindo Pharma Limited 2023-03-31
60687-0650-32 20 BLISTER PACK in 1 CARTON (60687-650-32) / 1 CAPSULE, EXT... Mesalamine American Health Packaging 2022-09-06
62332-0724-35 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62332-724-35) MESALAMINE Alembic Pharmaceuticals Inc. 2022-11-03
62332-0724-91 1000 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62332-724-91) MESALAMINE Alembic Pharmaceuticals Inc. 2022-11-03
65649-0103-01 1 BOTTLE in 1 CARTON (65649-103-01) / 4 CAPSULE, EXTENDED R... APRISO Salix Pharmaceuticals, Inc. 2008-10-31
65649-0103-02 1 BOTTLE in 1 CARTON (65649-103-02) / 120 CAPSULE, EXTENDED... APRISO Salix Pharmaceuticals, Inc. 2008-10-31
67877-0717-05 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (67877-717-05) Mesalamine Ascend Laboratories, LLC 2021-07-16
67877-0717-12 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (67877-717-12) Mesalamine Ascend Laboratories, LLC 2021-07-16
68382-0452-19 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (68382-452-19) Mesalamine Zydus Pharmaceuticals USA Inc. 2021-08-13
68682-0113-20 1 BOTTLE in 1 CARTON (68682-113-20) / 120 CAPSULE, EXTENDED... mesalamine Oceanside Pharmaceuticals 2018-07-19
70771-1625-07 120 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (70771-1625-7) Mesalamine Zydus Lifesciences Limited 2021-08-13
Observed labelers: Alembic Pharmaceuticals Inc. (2) · Alembic Pharmaceuticals Limited (2) · Ascend Laboratories, LLC (2) · Salix Pharmaceuticals, Inc. (2) · American Health Packaging (1) · Aurobindo Pharma Limited (1) · +10 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.